# Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

> **NCT06107868** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 6 (actual)

## Conditions studied

- Recurrent Ovarian Cancer
- Recurrent Uterine Cancer
- Metastatic Cancer
- Advanced Cancer

## Interventions

- **DRUG:** RP-6306
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06107868
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-01-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107868, "Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06107868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*